Maria Emilia Panzetta

Maria Emilia Panzetta

Auto-generated profile, based on publicly available information

Maria Emilia Panzetta

Duke

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 December 2018 in Frontiers in Microbiology
Verified
Journal Article
Open access
PDF file
MPMaria Emilia Panzetta
Maria Emilia Panzetta
RVRaphael H. Valdivia
Raphael H. Valdivia
HSHector Alex Saka
Hector Alex Saka
The Chlamydiaceae comprise a group of highly adapted bacterial pathogens sharing a unique intracellular lifestyle. Three Chlamydia species are pathogenic to humans: Chlamydia trachomatis, Chlamydia pneumoniae, and Chlamydia psittaci. C. trachomatis is the leading bacterial cause of sexually-transmitted infections and infectious blindness worldwide. Chlamydia pneumoniae is a major cause of community-acquired atypical pneumonia. C. psittaci primarily affects psittacine birds and can be transmitted to humans causing psittacosis, a potentially fatal form of pneumonia. As opposed to other bacterial pathogens, the spread of clinically relevant antimicrobial resistance genes does not seem to be a major problem for the treatment of Chlamydia infections. However, when exposed to stressing conditions, like those arising from exposure to antimicrobial stimuli, these bacteria undergo a temporary interruption in their replication cycle and enter a viable but non-cultivable state known as persistence. When the stressing conditions are removed, Chlamydia resumes replication and generation of infectious particles. This review gives an overview of the different survival strategies used by Chlamydia to evade the deleterious effects of penicillin and IFNγ, with a focus on the different models used to study Chlamydia persistence, their contribution to elucidating the molecular basis of this complex phenomenon and their potential implications for studies in animal models of infection.

21 September 2024 in Gut Microbes
Verified
Journal Article
Open access
MPMaria E. Panzetta
Maria E. Panzetta
RVRaphael H. Valdivia
Raphael H. Valdivia
Akkermansia sp are common members of the human gut microbiota. Multiple reports have emerged linking the abundance of A. muciniphila to health benefits and disease risk in humans and animals. This review highlights findings linking Akkermansia species in the gastrointestinal (GI) tract to health outcomes across a spectrum of disorders, encompassing those that affect the digestive, respiratory, urinary, and central nervous systems. The mechanism through which Akkermansia exerts a beneficial versus a detrimental effect on health is likely dependent on the genetic makeup of the host metabolic capacity and immunomodulatory properties of the strain, the competition or cooperation with other members of the host microbiota, as well as synergy with co-administered therapies.

10 April 2019 in Frontiers in Microbiology
Verified
Journal Article
Open access
PDF file
MPMaría E. Panzetta
María E. Panzetta
ALAgustín L. Luján
Agustín L. Luján
RBRobert J. Bastidas
Robert J. Bastidas
MDMaría T. Damiani
María T. Damiani
RVRaphael H. Valdivia
Raphael H. Valdivia
HSHéctor A. Saka
Héctor A. Saka
Chlamydia trachomatis is the most common sexually transmitted bacterial pathogen in humans and a frequent cause of asymptomatic, persistent infections leading to serious complications, particularly in young women. Chlamydia displays a unique obligate intracellular lifestyle involving the infectious elementary body and the replicative reticulate body. In the presence of stressors such as gamma-interferon (IFNγ) or beta-lactam antibiotics, C. trachomatis undergoes an interruption in its replication cycle and enters a viable but non-cultivable state. Upon removal of the stressors, surviving C. trachomatis resume cell division and developmental transitions. In this report, we describe a genetic screen to identify C. trachomatis mutants with defects in recovery from IFNγ- and/or penicillin-induced stress and characterized a chemically derived C. trachomatis mutant strain that exhibited a significant decrease in recovery from IFNγ- but not penicillin-induced stress. Through lateral gene transfer and targeted insertional gene inactivation we identified ptr, encoding a predicted protease, as a gene required for recovery from IFNγ-induced stress. A C. trachomatis LGV-L2 ptr-null strain displayed reduced generation of infectious progeny and impaired genome replication upon removal of IFNγ. This defect was restored by introducing a wild type copy of ptr on a plasmid, indicating that Ptr is required for a rapid growth upon removal of IFNγ. Ptr was expressed throughout the developmental cycle and localized to the inclusion lumen. Overall, our findings indicate that the putative secreted protease Ptr is required for C. trachomatis to specifically recover from IFNγ- but not penicillin-induced stress.

17 April 2025 in Research Square
Verified
Preprint
Open access
PDF file
RVRaphael Valdivia
Raphael Valdivia
MPMaria Emilia Panzetta
Maria Emilia Panzetta
KMKatherine Mueller
Katherine Mueller
JAJason Arnold
Jason Arnold
RPRaquel Perry
Raquel Perry
RBRichard Bedlack
Richard Bedlack
Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disease that can progress at varying rates; however, the factors influencing progression rates in ALS patients remain unknown. In this study, we report distinct microbiome and metabolomic signatures associated with ALS progression rates. Rapid progression rates were transferable to a genetic mouse model of ALS following a fecal microbiota transplant (FMT) from patients exhibiting rapid disease progression. By focusing on microbial and metabolic markers shared between the FMT donors and mouse recipients, we identified Phocaeicola vulgatus as a microbial biomarker for slow progression. Additionally, we found strain-level differences in P. vulgatus among ALS patients and isolated a strain that partially alleviated disease in mice that received microbiota linked with rapid progression. Identifying microbiota that accelerates ALS progression, along with strains of P. vulgatus and correlated metabolites that mitigate such accelerated diseases, reveals new avenues for potential therapeutic interventions.